Clinical Trial Update: A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating adoptive cell therapy with tumor infiltrating lymphocytes plus interleukin-2 for metastatic melanoma, given either alone or af…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Pembrolizumab (pembrolizumab)
• Tumor infiltrating lymphocyte (TIL) adoptive cell therapy (tumor infiltrating lymphocytes)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma | Phase 2 | Status: RECRUITING